Literature DB >> 417435

Procainamide-induced hemolytic anemia.

G W Jones, T L George, R D Bradley.   

Abstract

The paper reports a case of hemolytic anemia induced by procainamide hydrochloride treatment. Decreases in hemoglobin concentration are correlated with 11 months of procainamide treatment along with a marked increase in hemoglobin following cessation of the drug. The patient exhibited no symptoms suggestive of drug-induced Lupus Erythematosus that has been frequently reported as a sequela of procainamide therapy. Direct antiglobulin tests were consistently positive throughout the clinical course, and an ether-eluate prepared from the patient's red blood cells showed panagglutinability. The antibody in the eluate reacted with Rhnull, D--, LW negative, and U negative red blood cells without addition of procainamide or pretreatment of red blood cells with the drug. It is noted that this antibody reacts similarly to the antibody produced as a consequence of alpha-methyl-dopa therapy.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 417435     DOI: 10.1046/j.1537-2995.1978.18278160589.x

Source DB:  PubMed          Journal:  Transfusion        ISSN: 0041-1132            Impact factor:   3.157


  1 in total

1.  Low-dose procainamide: low risk of complications with long-term use.

Authors:  C van Pham; J Noguchi; F P Quismorio; L J Haywood
Journal:  J Natl Med Assoc       Date:  1983-07       Impact factor: 1.798

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.